Advertisement
Advertisement
BIO.B
Bio-Rad Laboratories, Inc. Class B
299.00
USDSponsored
+3.95
+1.34%
Feb 06, 09:31 UTC -5
Closed
After-Market
299.00
0.00
0.00%
BIO.B Earnings Reports
Positive Surprise Ratio
BIO.B beat 29 of 40 last estimates.
73%
Next Report
In 4 Days
Date of Next Report
Feb 12, 2026
Estimate for Q4 25 (Revenue/ EPS)
$700.89M
/$2.73
Implied change from Q3 25 (Revenue/ EPS)
+7.33%
/+21.33%
Implied change from Q4 24 (Revenue/ EPS)
+5.00%
/-5.86%
Bio-Rad Laboratories, Inc. Class B earnings per share and revenue
On Oct 29, 2025, BIO.B reported earnings of 2.25 USD per share (EPS) for Q3 25, beating the estimate of 1.95 USD, resulting in a 15.74% surprise. Revenue reached 653.00 million, compared to an expected 657.81 million, with a -0.73% difference.
Looking ahead to Q4 25, 6 analysts forecast an EPS of 2.73 USD, with revenue projected to reach 700.89 million USD, implying an increase of 21.33% EPS, and increase of 7.33% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
FAQ
What were Bio-Rad Laboratories, Inc. Class B's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Bio-Rad Laboratories, Inc. Class B reported EPS of $2.25, beating estimates by 15.74%, and revenue of $653.00M, -0.73% below expectations.
How did the market react to Bio-Rad Laboratories, Inc. Class B's Q3 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Bio-Rad Laboratories, Inc. Class B expected to report next?
The next earning report is scheduled for Feb 12, 2026.
What are the forecasts for Bio-Rad Laboratories, Inc. Class B's next earnings report?
Based on 6
analysts, Bio-Rad Laboratories, Inc. Class B is expected to report EPS of $2.73 and revenue of $700.89M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement